Most health insurance plans classify PRP (platelet-rich plasma) injections as “experimental, investigational, or unproven,” which means they won’t pay for them. This isn’t a temporary oversight or a paperwork issue. It reflects a specific set of regulatory and evidence gaps that keep PRP outside the coverage framework, even as millions of patients receive it each year for joint pain, tendon injuries, and arthritis.
The “Experimental” Label Is the Core Problem
When an insurer calls a treatment “experimental or investigational,” that’s a formal classification with real consequences. It means the insurer has reviewed the available clinical evidence and determined it doesn’t meet their threshold for proven effectiveness. Cigna, for example, considers PRP experimental for every condition and indication, full stop. Most other major insurers follow the same logic.
This classification isn’t arbitrary. Insurers generally require large, well-designed clinical trials showing that a treatment consistently works better than existing options before they’ll cover it. PRP has a substantial body of research behind it, but much of that research is contradictory, uses inconsistent methods, or follows patients for too short a time to draw firm conclusions. A systematic review of PRP for tendon-related chronic pain found that while some studies showed functional improvement, the differences in how PRP was prepared, which tendons were treated, and how outcomes were measured made it impossible to pool the results into a single reliable conclusion.
No Two PRP Injections Are the Same
One of the biggest obstacles to insurance coverage is something most patients never think about: there’s no standard PRP recipe. The treatment involves drawing your blood, spinning it in a centrifuge to concentrate the platelets, and injecting that concentrate into the problem area. But the details of that process vary enormously from one clinic to the next.
Different commercial kits use different centrifuge speeds, spinning times, and separation methods, producing final products with wildly different platelet concentrations and varying amounts of white blood cells. Some preparations are “leukocyte-rich” (containing white blood cells), others are “leukocyte-poor,” and the two may have different effects on inflammation. There are no universally accepted quality control benchmarks for platelet viability, white blood cell contamination, or the concentration of growth factors in the final product. Even the volume injected varies. For knee osteoarthritis alone, one set of guidelines recommends 4 to 8 mL per joint while another recommends 2 to 12 mL.
This lack of standardization creates a problem insurers can’t easily solve. If every PRP injection is essentially a different product, it’s nearly impossible to say “PRP works for condition X” in the definitive way that coverage decisions require. It also makes it difficult to compare one clinical trial to another, since the PRP used in each study may have been fundamentally different.
How the FDA Classifies PRP
The FDA does not approve PRP therapy itself for specific medical conditions. What the FDA clears are the devices, the centrifuge kits used to prepare PRP. And the cleared indications for most of these devices are narrow. Several PRP devices approved in 2024 were cleared specifically for preparing platelet-rich plasma to be mixed with bone graft material to improve its handling characteristics during orthopedic surgery. That’s a far cry from the way PRP is commonly marketed: as a standalone injection for knee arthritis, tennis elbow, or rotator cuff tears.
This regulatory gap matters because insurers look to FDA approval as a signal that a treatment has passed a meaningful evidence bar. When the devices themselves aren’t cleared for the conditions patients are seeking treatment for, insurers have another reason to withhold coverage.
The One Exception: Diabetic Wounds
Medicare does cover PRP in one specific situation: chronic non-healing diabetic wounds. As of April 2021, CMS covers PRP for diabetic wounds that haven’t responded to standard care, for up to 20 weeks, when the PRP is prepared using an FDA-cleared wound management device. Coverage beyond 20 weeks or for other types of chronic wounds (pressure ulcers, venous wounds) is decided by regional Medicare contractors on a case-by-case basis.
This exception highlights the coverage logic. For diabetic wounds, there was enough targeted clinical evidence to satisfy CMS that PRP provided a meaningful benefit. For orthopedic uses like knee osteoarthritis or tendon injuries, that same level of evidence hasn’t materialized in a form insurers find convincing.
The Medical Coding Issue
PRP injections are billed under CPT code 0232T. The “T” at the end is significant: it designates a Category III code, which the medical coding system reserves for “emerging technology” services. Category III codes are tracking codes, meant to collect data on new procedures. They don’t carry the same reimbursement weight as the permanent Category I codes used for established treatments. Many insurers automatically flag Category III procedures for denial or manual review, adding another structural barrier to coverage.
What Orthopedic Guidelines Actually Say
The situation is complicated by the fact that major orthopedic organizations do see value in PRP for certain conditions. Both the American Academy of Orthopaedic Surgeons (AAOS) and the European Society for Sports Traumatology (ESSKA) recommend PRP for mild to moderate knee osteoarthritis. Both acknowledge that PRP provides pain relief and improved joint function, and both consider it generally safe with minimal side effects.
But even these professional societies add important caveats. Evidence supporting structural improvements like cartilage regeneration remains limited. The two organizations disagree on preparation details like whether to use leukocyte-poor or leukocyte-rich formulations, how much to inject, and how many sessions to recommend. These unresolved questions give insurers room to maintain their “unproven” stance, even when clinical guidelines lean positive.
What You’ll Pay Out of Pocket
Without insurance coverage, PRP injections typically cost around $500 to $2,500 per session, with most treatments falling near $1,000. The price depends on your geographic area, the provider’s experience, and how many injections your treatment plan calls for. Knee osteoarthritis guidelines suggest one to four injections per treatment cycle, spaced one to three weeks apart, so total costs can reach several thousand dollars.
Some clinics offer payment plans or package pricing for multiple sessions. It’s worth asking whether the quoted price includes the blood draw, the PRP preparation kit, imaging guidance (like ultrasound), and the injection itself, since some providers bill these components separately.
Alternatives That Insurance Does Cover
Insurers expect patients to try conventional treatments first, and these are typically covered. Corticosteroid injections are well-established, relatively inexpensive, and almost always covered by insurance. They provide temporary pain relief, though their effects tend to diminish with repeated use. Hyaluronic acid injections, which act as a lubricant in the joint, are covered by some plans but not all, and the evidence for their effectiveness is mixed.
Physical therapy, oral anti-inflammatory medications, bracing, and activity modification are standard first-line treatments that insurance covers. For advanced osteoarthritis that hasn’t responded to conservative care, joint replacement surgery is the covered surgical option. Interestingly, a Cleveland Clinic analysis explored whether PRP could serve as a cost-effective alternative to knee replacement, noting that comparative studies tend to favor PRP over steroid and hyaluronic acid injections. But cost-effectiveness arguments haven’t yet shifted insurer policies.
What Would Need to Change
For PRP to gain broad insurance coverage, several things would need to happen in sequence. The field would need standardized preparation protocols so that “PRP” means the same thing from one clinic to the next. Large, well-controlled trials using those standardized protocols would need to show clear, lasting benefits over existing covered treatments. The FDA would need to clear PRP devices for the specific orthopedic and musculoskeletal indications patients are seeking. And the CPT code would need to graduate from Category III to Category I, signaling that the procedure has moved from experimental to established.
None of these steps are impossible, but each one takes years. In the meantime, PRP remains in a frustrating middle ground: promising enough that respected medical organizations recommend it for certain conditions, but not standardized or proven enough for insurers to pick up the tab.